APA (7th ed.) Citation

SR, D., TK, P., W, G., Y, Z., Y, Z., C, T., . . . T, B. (2023). Pretreatment and Posttreatment Tumor Metabolic Activity Assessed by FDG-PET/CT as Predictors of Tumor Recurrence and Survival Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. Advances in radiation oncology, 9(1), 101313. https://doi.org/10.1016/j.adro.2023.101313

Chicago Style (17th ed.) Citation

SR, Deshpande, Podder TK, Grubb W, Zhang Y, Zheng Y, Towe C, Linden P, Avril N, and Biswas T. "Pretreatment and Posttreatment Tumor Metabolic Activity Assessed by FDG-PET/CT as Predictors of Tumor Recurrence and Survival Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy." Advances in Radiation Oncology 9, no. 1 (2023): 101313. https://doi.org/10.1016/j.adro.2023.101313.

MLA (9th ed.) Citation

SR, Deshpande, et al. "Pretreatment and Posttreatment Tumor Metabolic Activity Assessed by FDG-PET/CT as Predictors of Tumor Recurrence and Survival Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy." Advances in Radiation Oncology, vol. 9, no. 1, 2023, p. 101313, https://doi.org/10.1016/j.adro.2023.101313.